8-K 1 a06-14837_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2006

SUNESIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

 

000-51531

 

94-3295878

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

341 Oyster Point Boulevard

 

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (650) 266-3500

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On June 29, 2006, Sunesis Pharmaceuticals, Inc., publicly disseminated a press release announcing that David C. Stump, M.D., and Homer L. Pearce, Ph.D., have been appointed as a Class I member and a Class II member, respectively, of its Board of Directors.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits.

99.1 Press Release dated June 29, 2006.

* * * * * * * * *

2



SIGNATURE(S)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SUNESIS PHARMACEUTICALS, INC.

 

 

 

 

 

Date: July 5, 2006

 

 

 

 

 

 

By:

 

/s/ DARYL B. WINTER, PH.D.

 

 

 

 

Daryl B. Winter, Ph.D.

 

 

 

 

Senior Vice President, General Counsel

 



Exhibit Index

Exhibit No.

 

Description

 

 

EX-99.1

 

Press Release dated June 29, 2006